Today: 2 July 2026
Coinbase stock price nudges higher after hours as Feb. 12 earnings date drops and Senate crypto bill hits pause
17 January 2026
2 mins read

Coinbase stock price nudges higher after hours as Feb. 12 earnings date drops and Senate crypto bill hits pause

New York, Jan 16, 2026, 19:08 (EST) — After-hours

  • After-hours trading saw Coinbase shares edge up after the company confirmed it will release its quarterly results on Feb. 12
  • A Senate committee put off debating a crypto market-structure bill after CEO Brian Armstrong voiced opposition to the latest draft
  • With Coinbase set to report earnings next week, traders are closely watching both Washington’s agenda and shifts in crypto prices

Shares of Coinbase Global rose in after-hours trading Friday after the crypto exchange said it will report fourth-quarter and full-year results on Feb. 12. The stock added $1.94, about 0.8%, closing at $241.15, up from $239.21 at the regular session’s end.

Coinbase is closing in on its earnings report just as Washington stays heavily engaged in crypto regulation. Although the company has pushed for clearer U.S. guidelines for years, it’s now pushing back against a bill designed to do just that.

A Senate panel put off debating a draft crypto regulation bill mere hours after Coinbase CEO Brian Armstrong publicly rejected it, Reuters reported. Armstrong posted on X that Coinbase would “rather have no bill than a bad bill.” At the same time, Senate Banking Committee Chair Tim Scott maintained lawmakers were “working in good faith.” Reuters

The bill, known as the Digital Asset Market Clarity Act, seeks to set clear rules on when crypto tokens count as securities or commodities and to outline the SEC’s regulatory authority. Armstrong highlighted tokenized equities and “stablecoin rewards,” which are yield-style perks firms offer to users holding tokens tied to the dollar.

Bitcoin held steady around $95,500 late in U.S. trading. Coinbase shares tend to track major crypto price moves closely, with trading volumes surging whenever tokens make big swings.

Coinbase said it will report earnings after the market closes on Thursday, Feb. 12, with a webcast to follow. The earnings call is set for 5:30 p.m. ET.

Investors are watching to see whether trading activity held up through year-end and if subscription-and-services revenue matched that pace despite weaker spot volumes. Coinbase has recently shifted focus toward non-trading revenue, though retail demand continues to fuel transaction fees—a key part of its income.

Stablecoin language is still a major sticking point. Even small tweaks to the rules on rewards might ripple through product design and hit margins. That’s without factoring in enforcement moves from the SEC and other regulators.

The calendar poses an immediate snag. The Senate Banking Committee’s session on the Clarity Act is now marked as “POSTPONED” on its site, leaving markets in limbo until lawmakers provide a new signal instead of the expected vote. Senate Banking Committee

The risk is straightforward: a fall in crypto prices or tough wording in the bill could slam the brakes on trading and user engagement. Coinbase remains vulnerable to headlines from regulators and courts, even if no new enforcement actions are taken.

Traders are focused on two key developments: fresh timing from senators on the stalled crypto bill, and Coinbase’s earnings report for February 12, set to drop after the bell. This will be the next important indicator of crypto trading demand and the health of the related business.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Regencell Bioscience (RGC) Drops Sharply, Trades Far Below May Offer Price as Sector Moves Up
    July 2, 2026, 11:17 AM EDT. Regencell Bioscience Holdings (NASDAQ:RGC) slid 6.6% to $7.50, now down 63% from the $20.30 price of its May registered-direct deal. That slump stands out with biotech names like iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) gaining 1.9%. RGC traded in a wide 25.1% range, topping out at $9.31 during the session but still far off the May offer. The company raised around $20 million in the offering, which saw a big institutional player take the lead. Regencell posted a $5.3 million net loss for the six months to December 2025, with R&D spend limited at $416,030. CEO Yat-Gai Au keeps a tight grip, holding 88.6% of the stock, as the firm works on TCM treatments for ADHD and autism.
Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls
Previous Story

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls

Semiconductor stocks rally as TSMC lifts 2026 capex to $56 billion; ASML hits $500 billion mark
Next Story

Semiconductor stocks rally as TSMC lifts 2026 capex to $56 billion; ASML hits $500 billion mark

Go toTop